Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.
Medicine (Baltimore)
; 103(28): e38789, 2024 Jul 12.
Article
em En
| MEDLINE
| ID: mdl-38996163
ABSTRACT
RATIONALE Acquired resistance still inevitably occurs in patients treated with third-generation TKI osimertinib. Although the EGFR L718Q mutation has been reported as a scarce mechanism of osimertinib resistance, advanced therapeutic strategies are still in development. In this report, we included 2 cases of patients who acquired EGFR L858R/L718Q mutation after osimertinib and were overcome by dacomitinib. PATIENT CONCERNS Case 1 A 77-year-old woman was diagnosed with stage IV lung adenocarcinoma. Case 2 A 64-year-old woman was diagnosed with stage IV lung adenocarcinoma. DIAGNOSES Case 1 The patient was diagnosed with adenocarcinoma with EGFR L858R mutation. Since then, treatment with gefitinib was administrated, leading to a progression-free survival of 18 months. The treatment was switched to osimertinib based on the detection of EGFR T790M mutation, resulting in a progression-free survival of 24 months. Subsequently, EGFR L718Q mutation was detected. Case 2 The patient was diagnosed with adenocarcinoma with EGFR L858R mutation. Icotinib was used as the first-line treatment for 7 months. Osimertinib was applied as the second-line treatment for 13 months based on the EGFR T790M mutation. Subsequently, EGFR L718Q mutation was detected. INTERVENTIONS:
Case 1 Dacomitinib was administered. Case 2 Dacomitinib was administered.OUTCOMES:
Case 1The progression-free survival was 8 months. Case 2 The progression-free survival was 3 months. LESSONS Dacomitinib is a potential treatment option for NSCLC patients with EGFR L718Q mutation after resistance to Osimertinib. Further research is needed to validate the efficacy of Dacomitinib in this context.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Acrilamidas
/
Carcinoma Pulmonar de Células não Pequenas
/
Resistencia a Medicamentos Antineoplásicos
/
Quinazolinonas
/
Receptores ErbB
/
Compostos de Anilina
/
Neoplasias Pulmonares
/
Mutação
Limite:
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Medicine (Baltimore)
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China